DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7xws68/vasculitis) has announced the addition of the "Vasculitis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AnGes MG, Inc.
- Aprogen, Inc.
- ChemoCentryx, Inc.
- Epirus Biopharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Hemostemix Ltd
- K-Stemcell Co., Ltd.
- Panacea Biotec Limited
- Pfizer Inc.
- Sandoz International GmbH
- Stempeutics Research Private Limited
- Teijin Pharma Limited
- XOMA Corporation
- beperminogene perplasmid
- immune globulin (human)
- Monoclonal Antibodies to Antagonize GPR4 for Vascular Inflammation
- rituximab biosimilar
For more information visit http://www.researchandmarkets.com/research/7xws68/vasculitis